Privia Health Group, Inc. PRVA 深 沪
已收盘 02-06 16:00:00 美东时间
21.99
+0.480
+2.23%
华盛通- 最 高22.07
- 今 开21.53
- 成交量 88.35万股
- 最 低 21.05
- 昨 收 21.51
- 总市值 27.05亿
- 52周最高 26.51
- 市盈率 静 192.05
- 换手率 0.72%
- 52周最低 18.77
- 委 比 22.69%
- 总股本 1.23亿
- 历史最高 50.77
- 量 比 0.97
- 振 幅 4.74%
- 历史最低 15.92
- 每 手 1
- 风险率 1.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
Privia Health Group will release its fourth-quarter and annual financial results for 2025 on February 26, 2026, before market open. The press release will be available at ir.priviahealth.com by 7:00 am ET, followed by a conference call at 8:00 am ET. Management will discuss results and future plans. The call can be accessed via webcast at ir.priviahealth.com/news-and-events/events-and-presentations or by phone (888-596-4144, Conference ID: 570488...
01-22 14:00
CMS new accountable care model seen benefitting value-based care providers
CMS on Thursday unveiled its new model for accountable care organizations (ACOs), a 10-year voluntary pilot program that aims to have health care providers provide value-based care. The Long-term Enha...
2025-12-19 06:23
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
Stephens & Co. Reiterates Overweight on Privia Health Gr, Maintains $32 Price Target
Stephens & Co. analyst Jeff Garro reiterates Privia Health Gr (NASDAQ:PRVA) with a Overweight and maintains $32 price target.
2025-12-04 22:16
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
2025-11-13 09:58
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
2025-11-07 23:20
